


(NAMs)





2025 4 FDA  
 AI NAMs NAMs AI

## New Approach Methodologies, NAMs


NAMs NAMs AI  
 (in vitro) (ex vivo) (in silico)

- 3D Organ-on-Chip MPS Organoid
- PBPK QSP QST


/



NAMs



## NAMs



## AI

AI

Target-to-hit Hit-to-lead Lead-to-PCC





ROS

**STEP**



HepG

3D -HepG2

Acetaminophen (APAP) Concentrations



3D -HepG2





CDE 2020

CRA

IND



Platelet Viability assay





ABT-263 24 CTG ADP 5 anti-CD42 anti-CD62P  
 ABT-263 ADP  
 CD62P+ cells

HepG2 mRNA



HepG2 mRNA siRNA 10 nM siRNA


PROTAC



Smarca2/4 PROTAC MV-4-11 (DMSO, 10 nM, 100 nM), A B PROTAC 10nM  
 Smarca2 Smarca4 100nM


## PDXO - HER2 EGFR

PDXO HER2 : &



PDXM-102C

